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Abstract
Introduction:	Endometrial	hyperplasia	is	differentiated	into	benign	or	premalignant.	
Two	histological	classifications	are	used	for	this	purpose:	World	Health	Organization	
(WHO)	classification,	based	on	cytological	atypia,	disregarding	glandular	complexity,	
and	endometrial	intraepithelial	neoplasia	(EIN)	classification,	based	on	several	differ-
ent	parameters.	B‐cell	 lymphoma	2	 (Bcl‐2)	 loss	has	been	studied	as	 immunohisto-
chemical	marker	with	the	aim	of	improving	the	differential	diagnosis	between	benign	
and	premalignant	hyperplasia.	We	aimed	to	evaluate:	(A)	Bcl‐2	loss	as	marker	of	en-
dometrial	precancer,	by	assessing	it	in	proliferative	endometrium,	benign	hyperpla-
sia,	premalignant	hyperplasia,	and	endometrial	cancer;	(B)	the	diagnostic	accuracy	of	
Bcl‐2	 in	 the	 differential	 diagnosis	 between	 benign	 and	 premalignant	 endometrial	 
hyperplasia;	(c)	how	the	results	change	according	to	the	histological	classification	and	
the	thresholds	of	Bcl‐2	expression	used.
Material and methods:	Electronic	databases	were	searched	from	their	inception	to	
March	2018.	All	studies	assessing	Bcl‐2	immunohistochemistry	in	endometrial	speci-
mens were included.
Results:	In	total,	20	observational	studies	assessing	1,278	specimens	were	included.	
Bcl‐2	 loss	 rates	were	not	 significantly	different	between	proliferative	endometrium	
and	benign	hyperplasia	(P	=	0.12)	and	between	premalignant	hyperplasia	and	endome-
trial	cancer	(P	=	0.53).	Among	hyperplasias,	Bcl‐2	loss	was	significantly	associated	with	
premalignancy,	according	to	both	the	WHO	(OR	=	4.39;	P	<	0.00001)	and	EIN	classifi-
cations	 (OR	=	6.07;	 P	=	0.01),	 and	 also	 with	 architecture	 complexity	 (OR	=	2.06;	
P	=	0.02).	Using	the	WHO	classification,	Bcl‐2	loss	showed	low	diagnostic	accuracy	in	
detecting	premalignant	hyperplasia	(area	under	the	curve	[AUC]	=	0.708),	with	a	sensi-
tivity	of	0.41,	a	 specificity	of	0.81,	a	positive	 likelihood	 ratio	of	3.22,	and	a	negative	
likelihood	ratio	of	0.69.	Using	the	EIN	classification,	accuracy	was	high	(AUC	=	0.938),	
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1  | INTRODUC TION
Endometrial	hyperplasia	is	defined	as	an	irregular	proliferation	of	en-
dometrial	glands,	characterized	by	an	increased	gland	:	stroma	ratio	
compared	with	proliferative	endometrium.1	Endometrial	hyperplasia	
includes	 benign	 proliferations	 caused	by	 the	 unopposed	 action	 of	
estrogens	and	premalignant	lesions,	which	have	a	considerable	risk	
of	progression	to	endometrial	cancer.2,3
While	benign	endometrial	hyperplasia	may	be	managed	by	follow‐
up,	 premalignant	 endometrial	 hyperplasia	 usually	 requires	hysterec-
tomy,	or	progestins	and	close	follow‐up	in	selected	cases.4	However,	
the	distinction	between	these	two	conditions	is	often	difficult.2
The	gold	standard	for	the	differential	diagnosis	is	the	histological	
examination,	which	is	based	on	two	possible	classification	systems:	
the	World	Health	Organization	(WHO)	system	and	the	endometrial	
intraepithelial	neoplasia	(EIN)	system.2,3
The	2014	WHO	system	is	based	on	the	presence	of	cytological	
atypia	 and	 distinguishes	 between	 premalignant	 atypical	 endome-
trial	hyperplasia	and	benign	endometrial	hyperplasia	without	atypia.	
Nuclear	atypia	may	 include	rounding,	enlargement,	pleomorphism,	
loss	of	polarity,	and	nucleoli.1	The	complexity	of	glandular	architec-
ture,	 included	 in	 the	 former	 classification	 (WHO,	 1994),	 has	 been	
excluded,	 although	 it	 appears	 to	be	 associated	with	higher	 risk	of	
progression	to	endometrial	cancer.1-3
The	 EIN	 system	 differentiates	 between	 premalignant	 EIN	 and	
benign	 endometrial	 hyperplasia	 based	 on	 the	 presence	 of	 three	
morphological	 parameters	 (glands	 exceeding	 stroma,	 lesion	 size	
>	1	mm	 and	 cytological	 differences	 with	 adjacent	 non‐neoplastic	
endometrium)	and	a	careful	exclusion	of	benign	mimics	(e.g.,	polyps	
and	secretory	endometrium)	and	cancer	 (maze‐like	glands,	solid	or	
cribriform	areas).2,3,5,6	The	EIN	system	classifies	a	considerable	per-
centage	of	endometrial	hyperplasia	without	atypia	but	with	complex	
architecture	as	premalignant.6	However,	several	concerns	have	been	
reported	for	the	histological	classification,	which	are	related	to	the	
pathologist	(low	reproducibility)	or	to	the	specimen	itself	(tissue	in-
adequacy,	artifact	changes	and	ambiguous	features).2,3,7
A	 great	 number	 of	 immunohistochemical	 markers	 have	 been	
studied	to	improve	the	reliability	of	the	diagnosis.	The	anti‐apoptotic	
protein	B‐cell	lymphoma	2	(Bcl‐2)	is	upregulated	through	the	actions	
of	 estrogens	 and	 its	 expression	 has	 been	 observed	 to	 increase	 in	
proliferative	 endometrium	 and	 in	 benign	 endometrial	 hyperplasia.	
Several	studies	have	found	a	 loss	of	Bcl‐2	expression	in	neoplastic	
endometrial	 samples	 (premalignant	 endometrial	 hyperplasia	 and	
endometrial	cancer).8,9	Therefore,	Bcl‐2	 loss	has	been	proposed	as	
a	 marker	 to	 detect	 intraepithelial	 neoplasia	 in	 endometrial	 speci-
mens.10However	the	role	of	Bcl‐2	loss	of	expression	in	endometrial	
carcinogenesis	 has	 never	 been	 clarified.	 Furthermore,	 its	 possible	
clinical	usefulness	in	the	differential	diagnosis	of	endometrial	hyper-
plasia	is	still	subject	to	debate.
Thus,	the	aims	of	this	study	were:	 (i)	to	assess	Bcl‐2	 immunohisto-
chemical	 expression	 in	 histological	 specimens	 of	 proliferative	 endo-
metrium,	 benign	 endometrial	 hyperplasia,	 premalignant	 endometrial	
hyperplasia	and	endometrial	cancer,	to	define	whether	or	not	Bcl‐2	loss	
of	expression	may	be	considered	a	marker	of	neoplasia;	(ii)	to	determine	
the	clinical	usefulness	of	immunohistochemistry	for	Bcl‐2	in	the	differen-
tial	diagnosis	between	benign	and	premalignant	endometrial	hyperplasia,	
through	analyses	of	diagnostic	accuracy;	and	(iii)	to	assess	how	the	results	
are	influenced	by	the	histological	criteria	used	to	classify	endometrial	hy-
perplasia	and	by	the	thresholds	of	Bcl‐2	expression	considered.
with	a	sensitivity	of	0.18,	a	specificity	of	0.97,	a	positive	likelihood	ratio	of	5.16	and	a	
negative	likelihood	ratio	of	0.86.	Thresholds	of	Bcl‐2	expression	not	involving	a	com-
plete	loss	showed	lower	diagnostic	accuracy	with	a	slight	increase	in	sensitivity,	but	a	
severe	decrease	in	specificity.
Conclusions:	B‐cell	lymphoma	2	loss	is	a	marker	of	endometrial	precancer,	with	a	high	
specificity	and	high	diagnostic	accuracy	if	the	EIN	classification	is	used.	Thresholds	of	
Bcl‐2	expression	not	involving	a	complete	loss	should	not	be	considered.	Bcl‐2	loss	in	
endometrial	hyperplasia	may	be	a	novel	indication	for	treatment	when	precancerous	
features	are	ambiguous	in	a	histological	examination.	Bcl‐2	loss	correlates	better	with	
EIN	classification	than	with	the	WHO	classification,	suggesting	that	glandular	com-
plexity	is	an	important	precancerous	feature.
K E Y W O R D S
apoptosis,	biomarker,	cancer,	endometrial	hyperplasia,	neoplasia
Key message
Using	endometrial	 intraepithelial	neoplasia	criteria,	B‐cell	
lymphoma	2	 (Bcl‐2)	 loss	 is	 a	 highly	 specific	 and	 accurate	
marker	of	endometrial	precancer.	Bcl‐2	loss	in	endometrial	
hyperplasia	may	be	a	novel	indication	for	treatment.
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2  | MATERIAL AND METHODS
The	study	protocol,	including	methods	for	electronic	search,	study	se-
lection,	risk	of	bias	assessment,	data	extraction,	and	data	analysis,	was	
designed	previously.	Two	authors	(AT,	AR)	independently	conducted	all	
stages	of	the	study;	disagreements	were	resolved	by	discussion	with	a	
third	author	(GS).	The	study	was	reported	according	to	the	Preferred	
Reporting	Item	for	Systematic	Reviews	and	Meta‐analyses	statement.
MEDLINE,	 EMBASE,	Web	 of	 Sciences,	 Scopus,	 ClinicalTrial.gov,	
OVID,	Cochrane	Library	and	Google	Scholar	were	searched	for	rele-
vant	articles	from	the	inception	of	each	database	to	March	2018,	using	
a	combination	of	the	following	text	words	and	all	their	synonyms	found	
on	Medical	SubHeading	(MeSH):	“endometrial	hyperplasia”;	“prolifera-
tive	endometrium”;	“endometrial	cancer”;	“endometrial	intraepithelial	
neoplasia”;	“EIN”;	“precancer”;	“premalignant”;	“precursor”;	“Bcl2”;	“B‐
cl	 2”;	 “B‐cell	 lymphoma	2”;	 “apoptosis”;	 “apoptotic”;	 “anti‐apoptotic”;	
“marker”;	“biomarker”;	“expression”;	“immunohistochemistry”;	“immu-
nohistochemical”.	All	relevant	references	were	also	assessed.
All	peer‐reviewed,	prospective	and	retrospective	studies	assess-
ing	 the	 immunohistochemical	 expression	 of	 Bcl‐2	 on	 histological	
specimens	 of	 proliferative	 endometrium,	 benign	 endometrial	 hy-
perplasias,	premalignant	endometrial	hyperplasias	and	endometrial	
cancer	were	included	in	this	systematic	review.	The	exclusion	crite-
ria	were:	 (i)	data	on	Bcl‐2	expression	not	available;	 (ii)	endometrial	
hyperplasia	unclassified;	(iii)	inclusion	of	only	benign	or	only	prema-
lignant	endometrial	hyperplasia;	(iv)	sample	size	of	<	5	endometrial	
hyperplasia;	(v)	case	reports	and	reviews;	(vi)	not	written	in	English;	
(vii)	 endometrial	 hyperplasia	 data	 overlapping	 with	 an	 already	 in-
cluded	study.
The	 risk	 of	 bias	 was	 assessed	 according	 to	 the	 revised	 Quality	
Assessment	of	Diagnostic	Accuracy	Studies.11	Four	domains	related	to	
the	risk	of	bias	were	assessed	in	each	study:	(i)	patient	selection	(ie,	in-
clusion	of	consecutive	patients);	(ii)	index	test	(ie,	unbiased	assessment	
of	Bcl‐2	immunohistochemical	expression),	(iii)	reference	standard	(ie,	
unbiased	histological	classification),	(iv)	flow	and	timing	(ie,	all	patients	
were	assessed	with	the	same	index	test	and	the	same	reference	stan-
dard).	Authors’	judgments	were	categorized	as	“low	risk,”	“high	risk,”	or	
“unclear	risk	of	bias.”	For	the	domains	1,	2,	and	3,	concerns	about	their	
applicability	to	the	included	studies	were	also	assessed.
Data	were	extracted	from	the	included	studies	without	modifi-
cation.	Contingency	2	×	2	tables	were	prepared	for	each	study,	re-
porting	two	dichotomous	qualitative	variables:	Bcl‐2	expression	and	
histological	diagnosis.	When	discrepancies	between	values	reported	
in	the	text	and	the	tables	were	found,	values	from	tables	were	used	
for	the	analysis.
The	immunohistochemical	expression	of	Bcl‐2	was	dichotomized	
into	“presence”	and	“loss”.	For	studies	that	did	not	dichotomize	Bcl‐2	
expression,	data	were	extracted	using	the	following	criteria	for	Bcl‐2	
loss:
•	 when	Bcl‐2	expression	was	graded	according	to	the	 intensity	of	
staining,	the	lowest	grade,	indicating	absence	of	expression,	indi-
cated	Bcl‐2	loss;
•	 when	Bcl‐2	was	graded	according	to	the	rate	of	stained	cells,	the	
lowest	grade	indicated	Bcl‐2	loss;
•	 when	Bcl‐2	expression	was	graded	using	a	 staining	 score	 (com-
bining	intensity	and	stained	cells	rate),	the	lowest	grade	indicated	
Bcl‐2	loss.
The	authors	in	one	study	were	contacted	to	obtain	the	additional	
unpublished	 data	 regarding	 Bcl‐2	 expression	 in	 benign	 endometrial	
hyperplasia.12
The	 histological	 diagnosis	 was	 dichotomized	 as	 proliferative	
endometrium	vs	benign	endometrial	hyperplasia,	benign	endome-
trial	hyperplasia	vs	premalignant	endometrial	hyperplasia,	and	pre-
malignant	endometrial	hyperplasia	vs	endometrial	cancer.	Benign	
endometrial	hyperplasia	included	non‐atypical	endometrial	hyper-
plasia	according	to	the	WHO	classification	or	benign	endometrial	
hyperplasia	 according	 to	 the	EIN	 classification;	 premalignant	 en-
dometrial	 hyperplasia	 included	 atypical	 endometrial	 hyperplasia	
according	to	the	WHO	classification	or	EIN	according	to	the	EIN	
classification.	 Regarding	 benign	 and	 premalignant	 endometrial	
hyperplasia,	 two	 groups	were	 composed	 according	 to	 the	 classi-
fication	system	used	(WHO	or	EIN).	Moreover,	a	third	group	was	
created	according	to	the	former	WHO	parameter	of	architecture	
complexity.
The	association	between	the	 two	variables	 (Bcl‐2	expression	and	
histological	diagnosis)	was	assessed	using	odds	ratios	(OR),	with	95%	CI	
and	a	significant	P value	<	0.05.	OR	was	calculated	for	each	study	and	as	
pooled	estimates,	and	reported	graphically	on	forest	plots.
The	inconsistency	index	(I2)	was	used	to	quantify	the	statistical	
heterogeneity	among	the	studies:	heterogeneity	was	considered	
insignificant	for	I2 <	25%,	low	for	I2 <	50%,	moderate	for	I2 <	75%,	
and	high	for	I2 ≥	75%.	In	case	of	I2 ≥	50%,	a	random	effect	model	
was	adopted;	otherwise,	a	fixed	effect	model	was	preferred.
Values	of	OR	found	in	the	three	groups	were	compared	by	using	
chi‐squared	test,	with	a	significant	P	value	<	0.05.
In	the	analysis	of	diagnostic	accuracy,	the	index	test	was	Bcl‐2	
immunohistochemical	expression	(loss	or	presence),	while	the	ref-
erence	standard	was	endometrial	hyperplasia	histology	(benign	or	
premalignant).	The	following	criteria	were	adopted:
•	 premalignant	endometrial	hyperplasia	with	Bcl‐2	 loss	were	con-
sidered	true	positives;
•	 premalignant	endometrial	hyperplasia	with	Bcl‐2	presence	were	
considered	false	negatives;
•	 benign	endometrial	hyperplasia	with	Bcl‐2	 loss	were	considered	
false	positives;
•	 benign	endometrial	hyperplasia	with	Bcl‐2	presence	were	consid-
ered	true	negatives.
Analyses	of	diagnostic	accuracy	were	performed	separately	for	the	
WHO	and	EIN	classifications.	The	diagnostic	accuracy	was	assessed	as	
sensitivity,	specificity,	positive	 likelihood	ratio	 (LR+),	and	negative	 likeli-
hood	ratio	(LR−)	with	95%	CI.	The	area	under	the	curve	(AUC)	was	cal-
culated	on	summary	receiver	operating	characteristic	curves.	Diagnostic	
4  |     TRAVAGLINO eT AL.
accuracy	was	considered	absent	for	AUC	≤	0.5,	low	for	0.5	<	AUC	≤	0.75,	
moderate	for	0.75	<	AUC	≤	0.9,	high	for	0.9	<	AUC	<	0.97,	and	very	high	
for	AUC	≥	0.97.	A	 random	effect	model	was	 planned	 previously,	 since	
a	 significant	 heterogeneity	 is	 expected	 in	meta‐analyses	 of	 diagnostic	
accuracy.13
Where	possible,	we	assessed	whether	 the	diagnostic	 accuracy	
could	be	 improved	using	different	 thresholds	of	 the	expression	of	
Bcl‐2.	Only	studies	considering	both	the	intensity	of	staining	and	the	
rate	of	stained	cells	were	suitable	for	such	analysis.
Statistical	analyses	were	performed	using	Review	Manager	5.3	
(Copenhagen:	The	Nordic	Cochrane	Center,	Cochrane	Collaboration,	
2014)	and	Meta‐DiSc	version	1.4	(Clinical	Biostatistics	Unit,	Ramon	
y	Cajal	Hospital,	Madrid,	Spain).
3  | RESULTS
Altogether	20	observational	studies9,10,12,14‐30	with	a	total	of	1,278	
specimens	(137	proliferative	endometrium,	676	endometrial	hyper-
plasia,	and	465	endometrial	cancer),	were	included	in	the	systematic	
review.	The	flow	diagram	reporting	the	process	of	study	selection	is	
shown	in	Figure	1.
A	total	of	17	studies	adopted	the	WHO	classification	system	and	
three	used	the	the	EIN	system.	Among	the	studies	using	the	WHO	
system,	eight	studies	differentiated	endometrial	hyperplasia	based	
on	cytological	atypia,	six	did	so	based	on	the	complexity	of	architec-
ture,	and	three	did	so	based	on	both	parameters.
Six	studies	dichotomized	Bcl‐2	expression,	five	graded	the	inten-
sity	 of	 staining,	 three	 assessed	 the	 rate	 of	 stained	 cells,	while	 six	
used	more	than	one	parameter.	Out	of	five	studies	using	a	combined	
score	 (intensity	 grade	 +stained	 cells	 rate),	 two	 allowed	 extracting	
data	for	the	analysis	of	the	thresholds	of	Bcl‐2	expression;	the	two	
scoring	systems	were	fully	comparable.12,30	All	studies	assessed	the	
expression	of	Bcl‐2	in	endometrial	glands.	The	characteristics	of	the	
included	studies	are	shown	in	Table	1.
The	risk	of	bias	among	the	included	studies	is	shown	in	Figure	2. 
For	 the	patients’	 selection	domain,	 three	 studies	were	 considered	
to	be	at	 low	risk	of	bias	 (since	they	 included	consecutive	patients)	
and	17	were	at	unclear	risk	 (because	they	did	not	report	selection	
criteria);	concerns	about	applicability	were	unclear	for	three	studies	
(one	assessed	several	different	human	neoplasms;	one	included	only	
endometrial	hyperplasia	treated	with	progestins;	one	selected	only	
non‐atypical	endometrial	hyperplasia	and	reclassified	them	accord-
ing	to	the	EIN	system).	For	the	index	test	domain,	10	studies	were	
considered	at	low	risk	of	bias	(since	they	considered	both	intensity	
and	distribution	of	immunostaining)	and	10	at	unclear	risk	(because	
they	 considered	 only	 one	 parameter).	 For	 the	 reference	 standard	
domain,	 six	 studies	 were	 considered	 at	 low	 risk	 of	 bias	 (since	 all	
specimens	were	re‐evaluated	by	several	authors	at	the	same	time)	
and	14	at	unclear	risk	(because	they	did	not	re‐evaluate	the	speci-
mens).	For	the	flow	and	timing	domain,	only	one	study	was	at	unclear	
risk	and	concern	(because	not	all	endometrial	hyperplasia	included	
were	assessed	by	immunohistochemistry),	while	the	other	19	were	
considered	at	low	risk	of	bias.	No	study	was	at	high	risk	of	bias.	No	
further	concerns	about	applicability	were	found.
3.1 | B‐cell lymphoma 2 expression and 
histological diagnosis
B‐cell	 lymphoma	2	 loss	was	not	significantly	more	common	 in	be-
nign	 endometrial	 hyperplasia	 than	 in	 proliferative	 endometrium	
(OR	=	1.85,	95%	CI,	0.86‐4.02;	P	=	0.12),	and	without	heterogeneity	
among	studies	(I2 =	0%)	(Figure	3a).
Among	endometrial	hyperplasia,	Bcl‐2	loss	was	significantly	as-
sociated	 with	 premalignant	 endometrial	 hyperplasia,	 according	 to	
both	WHO	and	EIN	systems:
•	 when	the	WHO	system	(cytological	atypia)	was	adopted,	the	OR	
was	4.39	(95%	CI,	2.56‐7.53;	P	<	0.00001)	with	insignificant	het-
erogeneity	(I2	=	22%)	(Figure	3b);
•	 when	 the	 EIN	 system	 was	 adopted,	 the	 OR	 was	 6.07	 (95%	 CI	
1.50‐24.56;	P	=	0.01),	with	no	heterogeneity	(I2 =	0%)	(Figure	3c).
The	difference	between	WHO	and	EIN	groups	was	not	significant	
(chi‐squared = 0.18; P	value	=	0.67)	(Figure	3c).
B‐cell	 lymphoma	 2	 was	 also	 significantly	 associated	 with	 the	
complexity	of	glandular	 architecture,	with	an	OR	of	2.06	 (95%	CI,	
1.13‐3.74;	 P	 value	 of	 0.02)	 and	 without	 heterogeneity	 (I2 =	0%).	
There	was	 no	 significant	 difference	with	 the	 group	 of	 cytological	
atypia	(chi‐squared =	3.39;	P	value	=	0.07)	(Figure	3d).
Among	neoplastic	samples,	Bcl‐2	loss	was	more	common	in	endo-
metrial	cancer	than	in	premalignant	endometrial	hyperplasia,	without	
F I G U R E  1  Flow	diagram	of	studies	identified	in	the	systematic	
review	using	Preferred	Reporting	Item	for	Systematic	Reviews	and	
Meta‐analyses]	template.	Bcl‐2,	B‐cell	lymphoma	2
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statistical	 significance	 (OR	=	1.32,	 95%	 CI,	 0.55‐3.15;	 P	=	0.53),	 and	
with	moderate	heterogeneity	(I2 =	57%)	(Figure	3d).
3.2 | Diagnostic accuracy
3.2.1 | WHO group
In	the	WHO	group	the	sensitivity	and	specificity	of	Bcl‐2	loss	in	detect-
ing	premalignant	endometrial	hyperplasia	were	0.41	(95%	CI,	0.33‐0.49)	
and	0.81	 (95%	CI,	0.75‐0.86),	 respectively,	with	LR+	and	LR−	of	3.22	
(95%	CI,	1.45‐7.14)	and	0.69	(95%	CI,	0.55‐0.88),	respectively.	The	diag-
nostic	accuracy	was	low,	with	an	AUC	of	0.708.	The	heterogeneity	was	
high	for	sensitivity	(I2 =	82%)	and	specificity	(I2 =	89.4%)	and	moderate	
for	LR+	(I2 =	50.5%)	and	LR−	(I2 =	61.4%)	(Figure	4).	Analyses	of	differ-
ent	thresholds	of	Bcl‐2	expression	were	not	available	due	to	the	lack	of	
studies	using	a	scoring	system	that	combined	the	intensity	of	staining	
and	the	rate	of	stained	cells.
3.2.2 | EIN group
In	the	EIN	group	we	were	able	to	perform	analyses	of	diagnostic	
accuracy	 for	 a	 complete	 loss	of	 expression	and	 for	 three	differ-
ent	 thresholds	 of	 expression.	 For	 a	 complete	 loss	 of	 Bcl‐2	 ex-
pression,	 its	sensitivity	and	specificity	 in	detecting	premalignant	
endometrial	hyperplasia	were	0.18	 (95%	CI,	0.08‐0.34)	and	0.97	
(95%	CI,	0.91‐1.00),	respectively,	with	LR+	and	LR−	of	5.16	(95%	
F I G U R E  2   (a)	Assessment	of	risk	of	
bias.	Summary	of	risk	of	bias	for	each	
study;	+	low;	–	high;	?	unclear	risk	of	bias.	
(b)	Risk	of	bias	graph	of	each	risk	of	bias	
item	presented	as	percentages	across	
all	included	studies	[Color	figure	can	be	
viewed	at	wileyonlinelibrary.com]
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CI,	 1.46‐18.40)	 and	 0.86	 (95%	 CI,	 0.75‐1.00),	 respectively.	 The	
diagnostic	 accuracy	was	 high,	 with	 an	 AUC	 of	 0.938	 calculated	
on	summary	receiver	operating	characteristic	curves.	The	hetero-
geneity	was	insignificant	for	sensitivity	(I2 =	45.6)	and	specificity	
(I2 =	44.3),	and	absent	for	LR+	(I2 =	0%)	and	LR−	(I2=0%)	(Figure	5).
For	 threshold	 I	 (weak	 intensity	 in	 ≤	33%	 cells),	 sensitivity	 and	
specificity	were	0.18	(95%	CI,	0.08‐0.34)	and	0.91	(95%	CI,	0.81‐0.97),	
respectively,	with	LR+	and	LR−	of	1.88	(95%	CI,	0.69‐5.16)	and	0.91	
(95%	CI,	0.77‐1.07),	 respectively.	Heterogeneity	was	absent	 for	all	
analyses (I2 =	0%).
F I G U R E  3  Forest	plots	reporting	graphically	odds	ratio	for	B‐cell	lymphoma	2	loss	of	expression	in:	(a)	benign	hyperplasia	vs	normal	
proliferative	endometrium;	(b)	atypical	vs	non‐atypical	hyperplasia;	(c)	Endometrial	intraepithelial	neoplasia	vs	benign	hyperplasia;	(d)	simple	
vs	complex	hyperplasia;	(e)	premalignant	hyperplasia	vs	cancer.	Odds	ratios	were	calculated	for	each	study	and	as	pooled	estimates	with	95%	
CI.	Bcl‐2,	B‐cell	lymphoma	2;	EH,	endometrial	hyperplasia;	LR,	likelihood	ratio;	MH,	Mantel‐Haenszel	method
F I G U R E  4  Forest	plots	reporting	graphically	diagnostic	accuracy	of	immunohistochemical	loss	of	B‐cell	lymphoma	2	expression	in	
differentiating	between	benign	and	premalignant	hyperplasia	as	defined	by	2014	WHO	criteria:	(a)	sensitivity;	(b)	specificity;	(c)	positive	
likelihood	ratio;	(d)	negative	likelihood	ratio;	(e)	area	under	the	curve	(AUC)	on	summary	receiver	operating	characteristic	curves	(SROC).	LR,	
likelihood	ratio	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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For	threshold	II	(weak	intensity	in	33%‐67%	cells	or	moderate	
intensity	in	≤	33%	cells),	sensitivity	and	specificity	were	0.26	(95%	
CI,	0.13‐0.43)	and	0.76	(95%	CI,	0.64‐0.85),	respectively,	with	LR+	
and	LR−	of	1.11	(95%	CI,	0.48‐2.60)	and	0.98	(95%	CI,	0.74‐1.29),	
respectively.	 Heterogeneity	 was	 absent	 for	 sensitivity	 (I2 =	0%),	
insignificant	for	specificity	(I2 =	2.9%)	and	LR+	(I2 =	24.7%),	low	for	
LR−	(I2 =	30.3%).
For	 threshold	 III	 (weak	 intensity	 in	 >	67%	 cells,	 moderate	
intensity	 in	 33%‐67%	 cells,	 or	 strong	 intensity	 in	 ≤	33%	 cells),	
sensitivity	 and	 specificity	 were	 0.47	 (95%	 CI,	 0.21‐2.82)	 and	
0.44	 (95%	CI	0.32‐0.57),	 respectively,	with	LR+	and	LR−	of	0.78	
(95%	 CI,	 0.48‐2.60)	 and	 1.26	 (95%	 CI,	 0.39‐4.05),	 respectively.	
Heterogeneity	was	high	for	sensitivity	(I2 =	77.2%),	LR+	(I2 =	84.8%)	
and	LR−	(I2 =	87.5%),	and	moderate	for	specificity	(I2 =	74.1%).
The	AUC	calculation	was	not	feasible	in	the	analyses	of	expres-
sion	thresholds.
4  | DISCUSSION
Our	study	showed	that	Bcl‐2	loss	was	significantly	associated	with	
premalignant	features	of	endometrial	hyperplasia,	while	no	signifi-
cant	 differences	 were	 found	 between	 proliferative	 endometrium	
and	 benign	 endometrial	 hyperplasia,	 and	 between	 premalignant	
F I G U R E  5  Forest	plots	reporting	graphically	diagnostic	accuracy	of	immunohistochemical	loss	of	B‐cell	lymphoma	2	expression	in	
differentiating	between	benign	and	premalignant	hyperplasia	as	defined	by	endometrial	intraepithelial	neoplasia	criteria:	(a)	sensitivity;	
(b)	specificity;	(c)	positive	likelihood	ratio;	(d)	negative	likelihood	ratio;	(e)	area	under	the	curve	(AUC)	on	summary	receiver	operating	
characteristic	curves.	LR,	likelihood	ratio	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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endometrial	 hyperplasia	 and	 endometrial	 cancer.	 These	 findings	
strongly	 suggest	 that	 Bcl‐2	 loss	 may	 be	 a	 marker	 of	 endometrial	
neoplasia,	and	they	are	compatible	with	scientific	evidence	on	Bcl‐2	
physiology.	In	fact,	as	Bcl‐2	is	under	hormonal	control,	its	expression	
is	expected	to	be	high	in	benign	proliferative	conditions	caused	by	
the	action	of	estrogens	such	as	proliferative	endometrium	and	be-
nign	endometrial	hyperplasia.8,9,31
Our	results	showed	there	was	a	stronger	association	between	
Bcl‐2	loss	and	the	premalignant	morphology	of	endometrial	hyper-
plasia	when	the	EIN	system	was	adopted.	Once	it	is	assumed	that	
Bcl‐2	 loss	 is	 a	marker	of	precancer,	 such	 results	 suggest	 that	 the	
EIN	criteria	 are	more	 reliable	 than	 the	WHO	criteria.	This	obser-
vation	 is	 in	agreement	with	several	 findings	 reported	 in	 the	 liter-
ature,	 supporting	 the	 view	 that	 the	EIN	 system	 is	more	 accurate	
than	 the	WHO	 system	 in	 predicting	 progression	 to	 endometrial	
cancer.2,3,6	However,	the	difference	between	the	OR	found	in	the	
two	 groups	was	 not	 significant	 (P	=	0.67).	 EIN	 criteria	 of	 prema-
lignancy	 include	glandular	crowding,	 lesion	size	>	1	mm,	different	
cytology	from	the	adjacent	endometrium,	exclusion	of	mimics	and	
cancer.3	On	the	other	hand,	the	WHO	system	is	based	on	cytolog-
ical	atypia	alone,	and	the	complexity	of	glandular	architecture	has	
been disregarded.1,2	However,	Kurman	et	al.	observed	a	higher	rate	
of	progression	to	cancer	 in	simple	atypical	endometrial	hyperpla-
sia	compared	with	complex	non‐atypical	endometrial	hyperplasia,	
thus	considering	cytological	atypia	as	the	crucial	feature	in	the	risk	
stratification.32	 Although	 Bcl‐2	 loss	 showed	 a	 stronger	 associa-
tion	with	atypia	than	complexity	(4.39	vs	2.06),	the	difference	be-
tween	the	two	OR	was	not	significant	(P	=	0.07).	In	fact,	it	has	been	
shown	that	complexity	is	associated	with	a	higher	risk	of	malignant	
progression.	The	study	by	Kurman	et	al	showed	that,	among	non‐
atypical	 endometrial	 hyperplasia,	 complex	 endometrial	 hyperpla-
sia	progresses	to	cancer	more	frequently	than	simple	endometrial	
hyperplasia.32	 Furthermore,	 Baak	 et	 al.	 reported	 similar	 rates	 of	
progression	between	complex	and	simple	atypical	endometrial	hy-
perplasia,	 showing	 that	 the	EIN	system	classifies	as	premalignant	
a	 considerable	 percentage	 of	 complex	 non‐atypical	 endometrial	
hyperplasias.6
As	 a	 diagnostic	 marker	 in	 the	 differential	 diagnosis	 between	
benign	 and	 premalignant	 endometrial	 hyperplasia	 the	 accuracy	 of	
Bcl‐2	 appears	 to	 vary	 according	 to	 the	 classification	 system	 ad-
opted.	 In	 fact,	 while	 in	 the	 WHO	 group	 the	 diagnostic	 accuracy	
was	low	(AUC	=	0.708),	 in	the	EIN	group	the	accuracy	become	high	
(AUC	=	0.938)	due	to	a	considerably	higher	specificity	compared	with	
the	WHO	group	(0.97	vs	0.81).	This	finding	means	that	Bcl‐2	loss	may	
frequently	be	 found	 in	non‐atypical	endometrial	hyperplasia,	which	
is	considered	benign	in	the	WHO	system.	Under	the	assumption	that	
Bcl‐2	loss	is	a	marker	of	premalignancy,	such	endometrial	hyperplasias	
would	actually	be	precancer	misdiagnosed	by	the	WHO	system.	As	
discussed	above,	complex	non‐atypical	endometrial	hyperplasia	may	
account	for	most	of	these	cases.
However,	 independent	 of	 the	 classification	 adopted,	 the	 sen-
sitivity	was	low,	indicating	that	only	a	minor	percentage	of	prema-
lignant	endometrial	hyperplasia	shows	the	loss	of	Bcl‐2	expression.	
Such	 limits	cannot	be	overcome,	even	by	 increasing	 the	 threshold	
of	 Bcl‐2	 expression	 to	 be	 considered.	 As	 the	 threshold	 increases,	
sensitivity	 improves	 slightly	 (complete	 loss:	 0.18→threshold	 I:	
0.18→threshold	 II:	 0.26→threshold	 III:	 0.44),	 but	 specificity	 dra-
matically	 worsens	 (0.97→0.91	→	0.76→0.44),	 as	 well	 as	 the	 LR+	
(5.16→1.88→1.11→0.78)	 and	 the	 LR−	 (0.86→0.91→0.98→1.26).	
This	 makes	 immunohistochemistry	 for	 Bcl‐2	 inadequate	 as	 a	
stand‐alone	 test	 in	 the	 routine	diagnosis	of	endometrial	hyperpla-
sia,	since	many	patients	at	risk	of	progression	would	be	missed.	On	
the	other	hand,	 the	specificity	of	Bcl‐2	 loss	 for	 the	EIN	criteria	of	
premalignancy	appeared	excellent.	Thus,	Bcl‐2	 loss	 in	endometrial	
F I G U R E  6  Forest	plots	reporting	graphically	sensitivity,	specificity,	positive,	and	negative	likelihood	ratio	of	immunohistochemical	
loss	of	B‐cell	lymphoma	2	(Bcl‐2)	expression	in	differentiating	between	benign	and	premalignant	hyperplasia	as	defined	by	endometrial	
intraepithelial	neoplasia	criteria,	based	on	three	thresholds	of	Bcl‐2	expression:	(a)	I	(weak	expression	in	<	33%	cells);	(b)	II	(weak	intensity	in	
33%‐67%	cells	or	moderate	intensity	in	<	33%	cells);	(c)	III	(weak	intensity	in	>	67%	cells	or	moderate	intensity	in	33%‐67%	cells	or	strong	
intensity	in	<	33%	cells)	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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hyperplasia	 should	 be	 considered	 to	 be	 strongly	 indicative	 of	 the	
neoplastic	process.	When	the	premalignant	features	in	endometrial	
hyperplasia	are	ambiguous	the	finding	of	Bcl‐2	loss	may	still	indicate	
treatment,	 especially	 in	presence	of	 a	 complex	 glandular	 architec-
ture.	Bcl‐2	loss	may	be	a	novel	indication	for	treatment	and	follow	up	
in	women	with	endometrial	hyperplasia.
The	value	of	Bcl‐2	may	be	confirmed	by	its	evaluation	as	a	prognos-
tic	marker	of	progression	to	cancer.	In	fact,	we	found	only	one	study	
that	 assessed	 Bcl‐2	 as	 a	 marker	 of	 the	 progression	 of	 endometrial	
hyperplasia	 to	 endometrial	 cancer,	 showing	 a	 significant	 association	
between	a	decreased	expression	(rate	of	stained	cells	≤	80%)	and	the	
subsequent	development	of	endometrial	cancer.33
As	Bcl‐2	expression	may	not	decrease	simultaneously	in	glands	
and	 stroma34	 it	would	 be	 interesting	 to	 study	 the	 possible	 rele-
vance	of	Bcl‐2	stromal	expression	 in	the	differential	diagnosis	of	
endometrial	hyperplasia.	Nevertheless,	given	the	recent	discover-
ies	on	the	genetics	of	endometrial	cancer,	the	need	for	a	molecular	
definition	of	endometrial	neoplastic	specimens	has	been	growing,	
as	well	as	the	search	for	cheaper	immunohistochemical	surrogates	
of	genetic	prognostic	markers.35	Thus,	the	importance	of	Bcl‐2	and	
other	immunohistochemical	markers	may	be	set	to	increase	in	the	
near	future.
To	 the	 best	 of	 our	 knowledge,	 this	 study	 may	 be	 the	 first	
meta‐analysis	 assessing	 the	 expression	 of	 Bcl‐2	 in	 endometrial	
hyperplasia.	We	 defined	 the	 association	 of	 Bcl‐2	 loss	with	 the	
neoplastic	nature	of	endometrial	hyperplasia,	and	 the	accuracy	
of	 immunohistochemistry	 for	 Bcl‐2	 in	 a	 differential	 diagnosis	
between	 benign	 and	 premalignant	 endometrial	 hyperplasia.	
Furthermore,	we	assessed	the	influence	of	the	histological	crite-
ria	adopted	on	the	results,	and	we	interpreted	the	results	based	
on	the	scientific	evidence	reported	in	the	literature.	On	the	other	
hand,	one	limitation	of	our	study	may	be	found	in	the	low	unifor-
mity	of	the	methods	among	the	included	studies.	In	fact,	several	
differences	were	found	with	regard	to	the	baseline	characteris-
tics	of	 the	patients	 (such	as	 age	and	body	mass	 index)	 and	 the	
type	of	sample	(such	as	hysteroscopic	biopsy,	curettage,	or	sur-
gical	 specimen).	 The	 selection	 criteria	 for	 participants	 differed	
among	 the	 studies,	 and	 in	most	 cases	 they	were	 not	 specified	
(Figure	2).	Further	 studies	 in	 this	 field	 should	 include	consecu-
tive	patients	to	avoid	spectrum	bias.
Histological	 slides	 were	 reviewed	 simultaneously	 by	 at	 least	
two	pathologists	 in	fewer	than	50%	of	the	included	studies,	creat-
ing	 a	 possible	 bias	 in	 the	 reference	 standard	 (Figure	 2).	However,	
statistical	heterogeneity	among	studies	was	 low	or	absent	 in	most	
of	 our	 analyses,	 giving	 solidity	 to	 our	 results.	 High	 heterogeneity	
was	observed	only	for	the	diagnostic	accuracy	analysis,	where	it	is	
expected.13
Another	 limitation	 may	 consist	 in	 the	 absence	 of	 a	 validated	
method	to	interpret	Bcl‐2	immunostaining	in	terms	of	the	intensity	of	
the	staining	and	the	rate	of	stained	cells.	Nonetheless,	we	considered	
only	a	complete	loss	of	Bcl‐2	expression	in	the	main	analysis,	limiting	
the	risk	of	bias	caused	by	the	low	reproducibility	of	a	qualitative	scor-
ing.	Moreover,	for	the	assessment	of	the	different	thresholds	of	Bcl‐2	
expression,	we	limited	the	analysis	only	to	studies	adopting	a	complete	
and	clearly	defined	scoring	system,	which	considered	both	the	intensity	
of	the	staining	and	the	rate	of	the	stained	cells.
5  | CONCLUSION
A	loss	of	immunohistochemical	expression	of	Bcl‐2	in	endometrial	hy-
perplasia	 is	significantly	associated	with	premalignancy,	regardless	of	
the	classification	system	adopted.	When	assessed	with	the	EIN	crite-
ria,	Bcl‐2	loss	appeared	as	a	highly	specific	marker	of	endometrial	pre-
cancer,	with	high	diagnostic	accuracy.	Thus,	 the	 finding	of	Bcl‐2	 loss	
in	endometrial	hyperplasia	might	be	a	novel	 indication	for	 treatment	
and	follow‐up,	especially	when	precancerous	features	are	ambiguous	
at	histological	examination.	Thresholds	of	Bcl‐2	expression	that	differ	
from	a	complete	loss	showed	a	lower	diagnostic	accuracy	and	their	use	
should	not	be	considered.	Our	results	also	suggest	that	EIN	classifica-
tion	system	is	more	reliable	than	the	WHO	system,	suggesting	that	the	
complexity	 of	 glandular	 architecture	 as	 a	 premalignant	 feature	 is	 an	
important	criterion.	However,	further	studies	examining	Bcl‐2	loss	as	
independent	prognostic	factor	are	needed	to	use	this	certain	marker	
for	treatment	in	the	absence	of	overt	precancerous	features	in	histo-
logical	examination.
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